Yvonne Saenger Gives a Rundown of Immunotherapy Agents for Melanoma
Yvonne Saenger, MD, from Columbia University, gives a rundown of the immunotherapy options for treating melanoma.
Yvonne Saenger, MD, Director of Melanoma Immunotherapy at Columbia University, talks about the immunotherapy agents currently available for melanoma.
Along with ipulimimab, pembrolizimab and nivolumab prolonging survival in patients with melanoma, she discusses the oncolytic virus, a novel therapy using a herpes virus that attacks tumor cells preferentially.
Cemiplimab as Adjuvant Therapy Improves DFS in High-Risk Cutaneous Squamous Cell Carcinoma
January 20th 2025Adjuvant cemiplimab demonstrated a statistically significant improvement in DFS compared to placebo in post-surgical patients with high-risk CSCC, impacting post-operative care considerations.
